← Back to Search

Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

Phase 1
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- Body Mass Index (BMI) is ≥ 18.0 to ≤ 29.9 kg/m2 after rounding to the nearest tenth at screening and upon initial confinement.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately up to 72 days
Awards & highlights
No Placebo-Only Group

Summary

This trial will assess the safety and movement of ABBV-154 through the body in adult healthy volunteers.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately up to 72 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately up to 72 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Apparent Terminal Phase Elimination Rate Constant (β)
Maximum Observed Plasma Concentration (Cmax)
Number of Participants with Adverse Events
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: ABBV-154 Dose BExperimental Treatment1 Intervention
Participants will receive subcutaneous dose of ABBV-154 Dose Formulation B.
Group II: ABBV-154 Dose AExperimental Treatment1 Intervention
Participants will receive subcutaneous dose of ABBV-154 Dose Formulation A.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-154 Dose Formulation A
2022
Completed Phase 1
~40
ABBV-154 Dose Formulation B
2022
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor
1,037 Previous Clinical Trials
522,977 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
458 Previous Clinical Trials
163,762 Total Patients Enrolled
~13 spots leftby Dec 2025